Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) Director Eric Sachetta acquired 10,925 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average price of $3.18 per share, with a total value of $34,741.50. Following the acquisition, the director directly owned 229,943 shares of the company’s stock, valued at $731,218.74. The trade was a 4.99% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Eric Sachetta also recently made the following trade(s):
- On Wednesday, August 26th, Eric Sachetta bought 9,708 shares of Sensus Healthcare stock. The stock was purchased at an average cost of $3.29 per share, with a total value of $31,939.32.
- On Monday, August 24th, Eric Sachetta acquired 34,697 shares of Sensus Healthcare stock. The shares were acquired at an average cost of $3.25 per share, for a total transaction of $112,765.25.
Sensus Healthcare Price Performance
NASDAQ SRTS opened at $3.52 on Friday. Sensus Healthcare, Inc. has a one year low of $2.66 and a one year high of $5.49. The firm has a market cap of $57.94 million, a P/E ratio of -3.74 and a beta of 1.10. The stock’s 50-day moving average is $3.05 and its 200-day moving average is $3.52.
Analysts Set New Price Targets
Several brokerages have recently weighed in on SRTS. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Lake Street Capital dropped their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Wall Street Zen cut Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Finally, Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $5.83.
Check Out Our Latest Research Report on Sensus Healthcare
Hedge Funds Weigh In On Sensus Healthcare
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pacific Ridge Capital Partners LLC raised its position in shares of Sensus Healthcare by 21.8% in the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after purchasing an additional 125,245 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Sensus Healthcare by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock worth $630,000 after buying an additional 5,316 shares during the period. Sachetta LLC boosted its holdings in shares of Sensus Healthcare by 6.8% during the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock worth $591,000 after buying an additional 9,500 shares during the period. Greenline Wealth Management LLC acquired a new position in Sensus Healthcare in the 4th quarter valued at about $513,000. Finally, North Star Investment Management Corp. acquired a new position in Sensus Healthcare in the 1st quarter valued at about $500,000. 25.30% of the stock is owned by institutional investors.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.
Further Reading
- Five stocks we like better than Sensus Healthcare
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
